Expression system selection plays a central role in determining the success of VHH antibody development. Factors such as expression yield, folding efficiency, post-translational modifications (PTMs), scalability, and cost all influence the suitability of a given system for research, diagnostic, or therapeutic use.
VHH antibodies, which are derived from the variable domains of camelid heavy-chain-only antibodies, are structurally small, monomeric, and often functional without complex modifications. While these features enable their expression in multiple systems, downstream requirements such as glycosylation or Fc-fusion formatting can dictate the optimal host.
Mammalian cells are essential for the production of VHH formats requiring human-like PTMs or Fc-mediated functionality. Cell lines such as CHO (Chinese hamster ovary) and HEK293 are widely used to express VHH-Fc constructs, bispecific nanobodies, or VHH-based fusion proteins intended for therapeutic use.
As noted by Liu et al. (2017), mammalian systems ensure proper folding, authentic N-glycosylation, and accurate signal peptide processing, which are parameters that are often crucial for functional Fc fusion and biologics targeting clinical applications. CHO cells are the dominant choice for GMP-grade production, while HEK293 is commonly used for rapid, transient expression in discovery and preclinical studies.
Expression in these systems typically involves transfection of plasmids carrying VHH-Fc constructs under CMV or EF1α promoters, followed by purification using Protein A affinity chromatography. Though expression levels are lower than microbial hosts, yields of 10–50 mg/L (transient) and up to 1 g/L (stable lines) are attainable with optimization.
Mammalian platforms offer a clear regulatory advantage, particularly when therapeutic-grade expression is required. Glycosylation fidelity, endotoxin-free processing, and well-characterized bioreactor workflows make CHO the preferred system for clinical-grade VHH-Fc biologics.
Limitations include:
Higher production cost per milligram
Longer timelines due to cell line development or transient transfection
Moderate yields compared to bacterial systems
Despite these trade-offs, mammalian expression remains essential for nanobody constructs intended for human administration, particularly when Fc fusion is required for half-life extension or effector function.
Recombinant Protein Production →
Due to their small size, monomeric structure, and lack of glycosylation requirements, VHHs are highly amenable to prokaryotic expression. E. coli is the most commonly used platform for VHH production in research and diagnostics, offering high yields, short culture times, and low cost.
Bacterial systems have been successfully used to express VHHs for immunoassay development, toxin neutralization, and biosensor design. Multiple formats—including monomers, dimers, and bi-paratopic VHHs—have been produced in E. coli with functional binding capabilities.
Preferred strains include:
BL21(DE3): Compatible with T7 promoters; used for IPTG-inducible expression.
Rosetta(DE3): Supports expression of rare codon-rich sequences.
Origami B: Optimized for oxidative cytoplasmic folding and disulfide bond formation.
Several engineering strategies are used to improve folding and solubility:
Periplasmic targeting via signal peptides (e.g., pelB) improves disulfide bond formation and reduces proteolytic degradation.
Chaperone co-expression (e.g., DsbC) enhances folding efficiency.
Refolding protocols allow recovery of functional VHHs from inclusion bodies when soluble expression fails.
Expression yields can reach 50-100 mg/L of purified VHH from periplasmic fractions, and up to several hundred mg/L from inclusion bodies followed by refolding.
According to Liu et al., properly folded VHHs from E. coli are highly stable and retain binding affinity even under harsh conditions, making them particularly suitable for point-of-care diagnostics, environmental detection, and industrial-scale assays.
Yeast expression systems such as Pichia pastoris and Saccharomyces cerevisiae provide a eukaryotic folding environment, allowing for secretion of VHHs into the culture medium. While glycosylation patterns differ from humans, yeast systems offer a balance between scalability and folding quality.
P. pastoris is favored for high-density fermentation, inducible expression via AOX1 promoters, and strong secretion signals (e.g., α-mating factor).
S. cerevisiae is more genetically tractable but has lower secretion efficiency.
Yeast systems offer:
Moderate PTMs (though with non-human glycan structures)
Improved folding and secretion vs. E. coli
Simplified downstream purification via secretion
However, they may introduce hypermannosylation, which can affect immunogenicity and stability in therapeutic contexts. Yeast expression is commonly used for generating reagents for diagnostics or imaging, but is less favored for clinical applications.
CFPS enables rapid, small-scale VHH production from linear or plasmid DNA templates without the need for living cells. This approach is useful for:
High-throughput VHH screening
Expression of toxic or aggregation-prone constructs
Incorporation of non-natural amino acids
Limitations include cost, scalability, and variable folding efficiency, particularly for complex formats.
Insect cells (e.g., Sf9) using baculovirus vectors and plants such as Nicotiana benthamiana have been explored for VHH expression. These platforms provide eukaryotic folding and secretion but face challenges in consistency, glycan heterogeneity, and downstream purification.
Plant-based nanobody expression for veterinary diagnostics and epitope tagging, though not as mainstream options for large-scale therapeutic development.
System | Yield | PTMs | Cost | Time | Scalability | Use Case |
Mammalian | Low–Medium | Yes | High | Slow | Clinical-scale | Therapeutics |
E. coli | High | No | Low | Fast | High | Research, diagnostics |
Yeast | Medium | Partial | Medium | Moderate | Moderate | Diagnostics, imaging |
Cell-Free | Variable | No | High | Fast | Low | High-throughput screening |
Insect/Plant | Medium | Partial | Medium | Moderate | Low–Moderate | Veterinary, niche uses |
Each expression system serves a specific segment of the VHH antibody development pipeline:
Mammalian cells are essential for VHH-Fc constructs intended for therapeutic use, offering authentic glycosylation and GMP-compatible manufacturing.
E. coli remains the first-line system for research, diagnostics, and early-stage screening due to its simplicity and yield.
Yeast systems fill a middle ground, useful for secreted formats and applications with moderate glycosylation tolerance.
CFPS and alternative hosts support specialized use cases, including rapid screening and expression of toxic or unstable constructs.
Ultimately, platform selection depends on target format, production scale, regulatory pathway, and budget constraints.
Selecting the appropriate expression system is essential for ensuring the functional integrity, yield, and downstream utility of VHH antibodies. While E. coli and mammalian platforms remain the primary systems for nanobody expression across research, diagnostic, and therapeutic applications, the choice must align with the molecular format, regulatory requirements, and project objectives.
At Biointron, we offer an end-to-end VHH antibody discovery platform designed for both speed and quality. Each program begins with a dedicated alpaca from our 300+ herd, enabling a robust and focused immune response. We generate high-diversity immune libraries (≥10⁸ clones) and apply customized phage display campaigns to maximize binder diversity and epitope coverage.
Our workflow delivers optimized expression and functional validation across systems, whether in E. coli for high-yield research-scale production or mammalian cells for therapeutic-grade constructs such as VHH-Fc fusions. Selected clones undergo ELISA, SPR, and FACS-based screening, with KD values routinely spanning from 10⁻⁶ to 10⁻¹¹ M, depending on assay design and target characteristics. Optional assays include internalization and ADCC for relevant formats.
Biointron's typical timeline from immunization to lead candidate is just 4-5 months. We support both user-supplied and internally produced antigens, and all deliverables include complete sequence data, expression and binding validation, prioritized lead tables, and purified VHH samples, along with recommendations for downstream development. All antibodies generated under your program remain your exclusive property.
References:
Liu, Y., & Huang, H. (2017). Expression of single-domain antibody in different systems. Applied Microbiology and Biotechnology, 102(2), 539–551. https://doi.org/10.1007/s00253-017-8644-3
As of the end of 2025, 21 ADCs have been approved globally, with four new approv……
Antibody engineering has progressed beyond classical depletion and neutralizatio……
The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in ……
The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo……
You can also contact us on the Scientist and Science Exchange marketplaces.
